ClinicalTrials.gg
RecruitingNCT07851259Updated Oct 26, 2026

A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase 2 interventional study of RO7965032 and Placebo in Geographic Atrophy Secondary to Age-Related Macular Degeneration, sponsored by Genentech, Inc.. Recruiting at 5 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Updated Oct 26, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Geographic Atrophy by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Geographic Atrophy · Hoffmann-La Roche.

Planned enrollment
5th of 14
321 · median 144
Started
2027
the only one that year
Phase 2
7 of 16
2 open now
Registered
16th of 16
by date

Among the 16 studies in Geographic Atrophy by Hoffmann-La Roche, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2027, is one of 7 in phase 2, and was the 16th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

2 of the 16 studies in Geographic Atrophy by Hoffmann-La Roche are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Geographic Atrophy by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

03

Conditions studied

  • Geographic Atrophy Secondary to Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ocular Inclusion Criteria for the Study Eye

  • BCVA score of >= 35 letters using the ETDRS VA chart at a starting distance of 4 meters
  • Lesions may be either extrafoveal or subfoveal

Ocular Inclusion Criteria for Both Eyes

  • Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging
  • Well-demarcated GA secondary to AMD

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria - History of , a severe allergic reaction or anaphylactic reaction to any component of the drug injection

Ocular Exclusion Criteria for the Study Eye

  • History of diabetic macular edema (DME), retinal vein occlusion, corneal transplant, retinal detachment, Stage 3 or 4 macular hole, optic neuropathy, or retinal dystrophy
  • Current or prior history of central serous retinopathy
  • Aphakia or absence of the posterior capsule in the study eye

Ocular Exclusion Criteria for the Non-Study Eye

- Non-functioning non-study eye defined as either BCVA of hand motion or worse or no physical presence of non-study eye (i.e., monocular)

Ocular Exclusion Criteria for Either Eye

  • Proliferative diabetic retinopathy
  • History of recurrent infectious or inflammatory ocular disease
  • Current or prior history of choroidal neovascularization (CNV) in either eye
  • Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
321 participants (estimated)

Study arms

  • Experimental
    RO7965032 Dose Level 1

    Participants will receive RO7965032.

    Drug: RO7965032

  • Experimental
    RO7965032 Dose Level 2

    Participants will receive RO7965032.

    Drug: RO7965032

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • DrugRO7965032

    RO7965032 will be administered as per the schedule defined in the protocol.

  • DrugPlacebo

    Placebo will be administered as per the schedule defined in the protocol.

06

What researchers measure

Primary outcomes

  1. Change of GA Lesion Area in the Study Eye

    Time frame: Baseline up to approximately 48 weeks

  2. Incidence and Severity of Ocular Adverse Events (AEs)

    Time frame: Up to approximately 72 Weeks

  3. Incidence and Severity of Non-Ocular AEs

    Time frame: Up to approximately 72 Weeks

Secondary outcomes

  1. Change of GA Lesion Area in the Study Eye

    Time frame: Baseline up to approximately 72 weeks

  2. Change from Baseline in Best Correct Visual Acuity (BCVA) Score on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart

    Time frame: Baseline up to approximately 48 weeks

  3. Change from Baseline in BCVA Score on the ETDRS Chart Under Low-luminance Conditions

    Time frame: Baseline up to approximately 48 weeks

  4. Incidence and Severity of Selected Findings in Ocular Examinations and Ocular Imaging

    Time frame: Up to approximately 72 Weeks

  5. Plasma Concentration of RO7965032

    Time frame: Baseline up to approximately 72 weeks

  6. Percent Change from Baseline in Levels of Target Protein in Plasma

    Time frame: Baseline up to approximately 72 weeks

  7. Percent Change from Baseline in Levels of Plasma Biomarker Activity

    Time frame: Baseline up to approximately 72 weeks

  8. Prevalence and Incidence of Anti-Drug Antibodies (ADAs)

    Time frame: Baseline up to approximately 72 weeks

  9. Recommended Dose of RO7965032

    Time frame: Up to approximately 72 Weeks

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2030, 43 months later.

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 43 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartEst.
Jan 8, 2027was Sep 2026
Primary completionEst.
Aug 21, 2030
CompletionEst.
Aug 21, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
5 sites added — first site in United States
Show 5 added (5 United States)
  • Bay Area Retina Specialists Medical Group - Vestrum - PPDS · Walnut Creek, United States
  • Piedmont Retina Specialists · Winston-Salem, United States
  • Erie Retina Research · Erie, United States
  • Texas Retina Associates - Arlington · Arlington, United States
  • Piedmont Eye Center · Lynchburg, United States
Oct 26, 2026
Start date
Sep 30, 2026→Jan 8, 2027
Oct 26, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    5 sites added — first site in United States
    Show 5 added (5 United States)
    • Bay Area Retina Specialists Medical Group - Vestrum - PPDS · Walnut Creek, United States
    • Piedmont Retina Specialists · Winston-Salem, United States
    • Erie Retina Research · Erie, United States
    • Texas Retina Associates - Arlington · Arlington, United States
    • Piedmont Eye Center · Lynchburg, United States
    Start date Sep 30, 2026→Jan 8, 2027
    + 1 other change: verification date
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851259
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Jan 8, 2027 (estimated)
Primary completion
Aug 21, 2030 (estimated)
Completion
Aug 21, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Reference Study ID Number: XR46785 https://forpatients.roche.com/No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion